Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Wilschanski

Showing results (21-30 of 38) with videos related to

Pageof 4
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 2, 2017
Real life practice of sweat testing in EuropeN Cirilli, K W Southern, R Buzzetti, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 22, 2022
Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programmeN Cirilli, K W Southern, J Barben, et al.
Pediatrics|January 26, 1999
Clinical and genetic risk factors for cystic fibrosis-related liver diseaseM Wilschanski, J Rivlin, S Cohen, et al.
Nature Genetics|March 1, 1996
Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factorR Rozmahel, M Wilschanski, A Matin, et al.
Hepatology (Baltimore, Md.)|November 1, 1995
Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysisM Wilschanski, P Chait, J A Wade, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 28, 2020
Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)M W Konstan, D R VanDevanter, S M Rowe, et al.
Human Gene Therapy|April 3, 1998
Assessment of the efficacy of in vivo CFTR protein replacement therapy in CF miceM Ramjeesingh, L J Huan, M Wilschanski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 7, 2022
ECFS standards of care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunctionI Sermet-Gaudelus, E Girodon, F Vermeulen, et al.
Thorax|March 26, 2009
Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosisC Goubau, M Wilschanski, V Skalická, et al.
The European Respiratory Journal|August 9, 2001
Nasal potential difference measurements in patients with atypical cystic fibrosisM Wilschanski, H Famini, N Strauss-Liviatan, et al.
Pageof 4

Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 2, 2017
Real life practice of sweat testing in EuropeN Cirilli, K W Southern, R Buzzetti, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 22, 2022
Standards of care guidance for sweat testing; phase two of the ECFS quality improvement programmeN Cirilli, K W Southern, J Barben, et al.
Pediatrics|January 26, 1999
Clinical and genetic risk factors for cystic fibrosis-related liver diseaseM Wilschanski, J Rivlin, S Cohen, et al.
Nature Genetics|March 1, 1996
Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factorR Rozmahel, M Wilschanski, A Matin, et al.
Hepatology (Baltimore, Md.)|November 1, 1995
Primary sclerosing cholangitis in 32 children: clinical, laboratory, and radiographic features, with survival analysisM Wilschanski, P Chait, J A Wade, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|January 28, 2020
Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)M W Konstan, D R VanDevanter, S M Rowe, et al.
Human Gene Therapy|April 3, 1998
Assessment of the efficacy of in vivo CFTR protein replacement therapy in CF miceM Ramjeesingh, L J Huan, M Wilschanski, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 7, 2022
ECFS standards of care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunctionI Sermet-Gaudelus, E Girodon, F Vermeulen, et al.
Thorax|March 26, 2009
Phenotypic characterisation of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosisC Goubau, M Wilschanski, V Skalická, et al.
The European Respiratory Journal|August 9, 2001
Nasal potential difference measurements in patients with atypical cystic fibrosisM Wilschanski, H Famini, N Strauss-Liviatan, et al.
Pageof 4